Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 3 on this page, newest registry updates first. Search checked 2026-11-08 17:38 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase not reported / not applicableCompletedOBSERVATIONAL

Phase III Trial of CUV1647 in Polymorphic Light Eruption (PLE)

ClinicalTrials.gov · NCT00472901 · Registry updated: 2011-10-05

Condition / research focus: Polymorphic Light Eruption (PLE)
Sponsor: Clinuvel Pharmaceuticals Limited
Countries with listed sites: Australia · Austria · United Kingdom
Registry dates and results: Start: 2007-05. Completion: 2010-09 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Afamelanotide (CUV1647) (drug)

Where the study takes place — 3 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

St Vincents Hospital
Melbourne, Australia
Site recruitment: Not reported
Medical University of Vienna
Vienna, Austria
Site recruitment: Not reported
Hope Hospital
Manchester, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2UnknownINTERVENTIONAL

Phase II AK Study in Organ Transplant Patients

ClinicalTrials.gov · NCT00829192 · Registry updated: 2010-12-06

Condition / research focus: Actinic Keratoses; Carcinoma, Squamous Cell; Organ Transplant Recipients
Sponsor: Clinuvel Pharmaceuticals Limited
Countries with listed sites: Australia · Belgium · France · Germany · Italy · Sweden · Switzerland
Registry dates and results: Start: 2007-11. Completion: 2012-08 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Afamelanotide (CUV1647) (drug)
Placebo (drug)

Where the study takes place — 12 listed sites

The Princess Alexandra Hospital
Brisbane, Queensland, Australia
Site recruitment: Not reported
The Queen Elizabeth Hospital
Adelaide, South Australia, Australia
Site recruitment: Not reported
The Royal Melbourne Hospital
Melbourne, Victoria, Australia
Site recruitment: Not reported
Hospital Erasme
Brussels, Belgium
Site recruitment: Not reported
Gent University Hospital
Ghent, Belgium
Site recruitment: Not reported
University Hospital
Besançon, France
Site recruitment: Not reported
Charité Univeritätsklinikum
Berlin, Germany
Site recruitment: Not reported
Kiel University Hospital
Kiel, Germany
Site recruitment: Not reported
Ospedali Riuniti di Bergamo
Bergamo, Italy
Site recruitment: Not reported
University of Padua
Padua, Italy
Site recruitment: Not reported
Karolinska University Hospital
Stockholm, Sweden
Site recruitment: Not reported
Universitätsspital Zürich
Zurich, Switzerland
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Phase II Solar Urticaria (SU) Pilot Study

ClinicalTrials.gov · NCT00859534 · Registry updated: 2009-09-15

Condition / research focus: Solar Urticaria
Sponsor: Clinuvel Pharmaceuticals Limited
Countries with listed sites: United Kingdom
Registry dates and results: Start: 2008-12. Completion: 2009-07 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

afamelanotide (drug)

Where the study takes place — 1 listed sites

Salford Royal Foundation Hospital (Hope Hospital)
Manchester, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

Matching records; showing 3 on this page, newest registry updates first. Search checked 2026-11-08 17:38 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase not reported / not applicableCompletedOBSERVATIONAL

Phase III Trial of CUV1647 in Polymorphic Light Eruption (PLE)

ClinicalTrials.gov · NCT00472901 · Registry updated: 2011-10-05

Condition / research focus: Polymorphic Light Eruption (PLE)
Sponsor: Clinuvel Pharmaceuticals Limited
Countries with listed sites: Australia · Austria · United Kingdom
Registry dates and results: Start: 2007-05. Completion: 2010-09 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Afamelanotide (CUV1647) (drug)

Where the study takes place — 3 listed sites

St Vincents Hospital
Melbourne, Australia
Site recruitment: Not reported
Medical University of Vienna
Vienna, Austria
Site recruitment: Not reported
Hope Hospital
Manchester, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2UnknownINTERVENTIONAL

Phase II AK Study in Organ Transplant Patients

ClinicalTrials.gov · NCT00829192 · Registry updated: 2010-12-06

Condition / research focus: Actinic Keratoses; Carcinoma, Squamous Cell; Organ Transplant Recipients
Sponsor: Clinuvel Pharmaceuticals Limited
Countries with listed sites: Australia · Belgium · France · Germany · Italy · Sweden · Switzerland
Registry dates and results: Start: 2007-11. Completion: 2012-08 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Afamelanotide (CUV1647) (drug)
Placebo (drug)

Where the study takes place — 12 listed sites

The Princess Alexandra Hospital
Brisbane, Queensland, Australia
Site recruitment: Not reported
The Queen Elizabeth Hospital
Adelaide, South Australia, Australia
Site recruitment: Not reported
The Royal Melbourne Hospital
Melbourne, Victoria, Australia
Site recruitment: Not reported
Hospital Erasme
Brussels, Belgium
Site recruitment: Not reported
Gent University Hospital
Ghent, Belgium
Site recruitment: Not reported
University Hospital
Besançon, France
Site recruitment: Not reported
Charité Univeritätsklinikum
Berlin, Germany
Site recruitment: Not reported
Kiel University Hospital
Kiel, Germany
Site recruitment: Not reported
Ospedali Riuniti di Bergamo
Bergamo, Italy
Site recruitment: Not reported
University of Padua
Padua, Italy
Site recruitment: Not reported
Karolinska University Hospital
Stockholm, Sweden
Site recruitment: Not reported
Universitätsspital Zürich
Zurich, Switzerland
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Phase II Solar Urticaria (SU) Pilot Study

ClinicalTrials.gov · NCT00859534 · Registry updated: 2009-09-15

Condition / research focus: Solar Urticaria
Sponsor: Clinuvel Pharmaceuticals Limited
Countries with listed sites: United Kingdom
Registry dates and results: Start: 2008-12. Completion: 2009-07 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

afamelanotide (drug)

Where the study takes place — 1 listed sites

Salford Royal Foundation Hospital (Hope Hospital)
Manchester, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →